Vevye: A New Cyclosporine Solution for Dry Eye Disease
XTalks
JUNE 14, 2023
percent received approval from the US Food and Drug Administration (FDA) to treat dry eye disease. Furthermore, the bioavailability of the active pharmaceutical ingredient (API) into the cornea is up to four times stronger with EyeSol technology. Attendees will understand best practices for novel drug delivery design and development.
Let's personalize your content